Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

1.

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC.

J Psychopharmacol. 2010 Mar;24(3):297-307. doi: 10.1177/0269881108099423. Epub 2009 Jan 22.

PMID:
19164490
[PubMed - indexed for MEDLINE]
2.

A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.

Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC.

J Clin Psychopharmacol. 2011 Dec;31(6):763-8. doi: 10.1097/JCP.0b013e3182367aee.

PMID:
22020357
[PubMed - indexed for MEDLINE]
3.

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

Denys D, de Geus F, van Megen HJ, Westenberg HG.

J Clin Psychiatry. 2004 Aug;65(8):1040-8.

PMID:
15323587
[PubMed - indexed for MEDLINE]
4.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
[PubMed - indexed for MEDLINE]
5.

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.

Francobandiera G.

Can J Psychiatry. 2001 May;46(4):356-8.

PMID:
11387793
[PubMed - indexed for MEDLINE]
6.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.

Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.

PMID:
16585942
[PubMed - indexed for MEDLINE]
7.

Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.

Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A.

J Clin Psychiatry. 2005 Jan;66(1):73-9.

PMID:
15669891
[PubMed - indexed for MEDLINE]
8.

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

Atmaca M, Kuloglu M, Tezcan E, Gecici O.

Int Clin Psychopharmacol. 2002 May;17(3):115-9.

PMID:
11981352
[PubMed - indexed for MEDLINE]
9.

Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?

Denys D, Fineberg N, Carey PD, Stein DJ.

Biol Psychiatry. 2007 Feb 1;61(3):412-4.

PMID:
17241831
[PubMed - indexed for MEDLINE]
10.

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.

Mohr N, Vythilingum B, Emsley RA, Stein DJ.

Int Clin Psychopharmacol. 2002 Jan;17(1):37-40.

PMID:
11800505
[PubMed - indexed for MEDLINE]
11.

Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.

Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA.

J Clin Psychopharmacol. 1996 Apr;16(2):121-9.

PMID:
8690827
[PubMed - indexed for MEDLINE]
12.

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].

Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ.

BMC Psychiatry. 2005 Jan 24;5:5.

PMID:
15667657
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
[PubMed - indexed for MEDLINE]
14.

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Aboujaoude E, Barry JJ, Gamel N.

J Clin Psychopharmacol. 2009 Feb;29(1):51-5. doi: 10.1097/JCP.0b013e318192e9a4.

PMID:
19142108
[PubMed - indexed for MEDLINE]
15.

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.

Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ.

J Clin Psychiatry. 2009 Jun;70(6):863-8. doi: 10.4088/JCP.08m04369. Epub 2009 May 5.

PMID:
19422759
[PubMed - indexed for MEDLINE]
16.

Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series.

Dell'Osso B, Mundo E, Altamura AC.

CNS Spectr. 2006 Nov;11(11):879-83; quiz 885.

PMID:
17075559
[PubMed - indexed for MEDLINE]
17.

Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?

Maina G, Albert U, Ziero S, Bogetto F.

Int Clin Psychopharmacol. 2003 Jan;18(1):23-8.

PMID:
12490771
[PubMed - indexed for MEDLINE]
18.

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

Bogetto F, Bellino S, Vaschetto P, Ziero S.

Psychiatry Res. 2000 Oct 30;96(2):91-8.

PMID:
11063782
[PubMed - indexed for MEDLINE]
19.

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.

Ak M, Bulut SD, Bozkurt A, Ozsahin A.

Adv Ther. 2011 Apr;28(4):341-8. doi: 10.1007/s12325-011-0011-7. Epub 2011 Mar 21.

PMID:
21437763
[PubMed - indexed for MEDLINE]
20.

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Ringold AL, Elliott MA.

J Clin Psychiatry. 2000 Jul;61(7):514-7.

PMID:
10937610
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk